$RZLT earnings report

Rezolute reported a $18.5 million first-quarter fiscal 2027 net loss, ended the quarter with $90.0 million of cash, cash equivalents and marketable securities, and expects tumor HI topline results by mid-December 2026. AlphAI read Rezolute's Q1 FY2027 filing as mixed. 2 quarters are on record below.

Q1 FY2027

AlphAI · Earnings readRZLT · First Quarter Fiscal 2027 · ended September 30, 2026

Rezolute reported a $18.5 million first-quarter fiscal 2027 net loss, ended the quarter with $90.0 million of cash, cash equivalents and marketable securities, and expects tumor HI topline results by mid-December 2026.

→Mixed quarter

Operating expenses declined modestly year over year, but net loss increased and cash, cash equivalents and marketable securities declined from June 30, 2026. The clinical outlook includes an imminent tumor HI readout and an FDA-recommended BLA path for congenital HI, while the congenital HI pivotal study did not meet its primary endpoint.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, three months ended September 30GAAP$12.81M––
Research and development share-based compensation expense, first quarter fiscal 2027GAAP$1.5M––
General and administrative expenses, three months ended September 30GAAP$6.58M––
General and administrative share-based compensation expense, first quarter fiscal 2027GAAP$1.8M––
Total operating expenses, three months ended September 30GAAP$19.39M––
Loss from operations, three months ended September 30GAAP−$19.39M––
Non-operating income, net, three months ended September 30GAAP$898K––
Net loss, three months ended September 30GAAP−$18.49M––
Basic and diluted net loss per common share, three months ended September 30GAAP$ (0.18 )––
Shares used to compute basic and diluted net loss per common share, three months ended September 30GAAP104.8M––
Cash, cash equivalents and investments in marketable securities, September 30, 2026GAAP$90M––
Cash and cash equivalents, September 30, 2026GAAP$8.15M––
Investments in marketable debt securities, September 30, 2026GAAP81.85M––
Working capital, September 30, 2026GAAP84.37M––
Total assets, September 30, 2026GAAP96.01M––
Accumulated deficit, September 30, 2026GAAP−499.9M––
Total stockholders’ equity, September 30, 2026GAAP85.95M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2027 outlook

  • NoteTopline results from the upLIFT Phase 3 study in tumor HI are expected by mid-December 2026.
  • NotePlan to submit a BLA for ersodetug for one or potentially both indications in 2027.
  • NotePotential $5 billion combined market opportunity.

What drove it

  • R&D expense decreased primarily due to decreased manufacturing costs for ersodetug and patient affairs costs, partially offset by increased employee-related stock-based compensation expense.
  • G&A expense decreased primarily due to a decrease in professional fees, partially offset by increased employee-related stock-based compensation expense.
  • Enrollment is complete in upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for tumor HI.
  • 7 of the 8 participants enrolled in the first half of the upLIFT study met the responder criterion for the study’s primary endpoint, and each achieved complete discontinuation of intravenous glucose with the administration of ersodetug.
  • FDA recommended that the Company file for review under a BLA for congenital HI after holding a pre-BLA meeting.

Concerns

  • The sunRIZE Phase 3 study in congenital HI did not meet its primary endpoint because reductions in hypoglycemia events by finger-stick SMBG were not statistically significant compared to placebo.
  • The eighth participant in the first half of the upLIFT study discontinued study drug shortly after enrollment to pursue hospice care at home and was considered a non-responder for the primary endpoint.
  • Cash, cash equivalents and investments in marketable securities declined to $90.0 million as of September 30, 2026, from $107.8 million as of June 30, 2026.
  • Net loss was $ (18,487 ) (in thousands), compared with $ (18,150 ) (in thousands) for the same period a year ago.
  • The Company stated there can be no assurance that FDA will agree that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support approval of ersodetug for congenital HI.

What to watch

  • Topline results from the tumor HI upLIFT study, expected by mid-December 2026.
  • The ongoing open-label extension phase of the sunRIZE study and indicators of glycemic control, including use of background standard of care therapies.
  • The planned BLA submission for ersodetug for one or potentially both indications in 2027.
  • Cash, cash equivalents and investments in marketable securities following the September 30, 2026 balance of $90.0 million.

Balance sheet and cash flow

  • Cash, cash equivalents and investments in marketable securities were $90.0 million as of September 30, 2026, compared with $107.8 million as of June 30, 2026.
  • Cash and cash equivalents were $ 8,150 (in thousands) as of September 30, 2026, compared with $ 10,615 (in thousands) as of June 30, 2026.
  • Investments in marketable debt securities were 81,849 (in thousands) as of September 30, 2026, compared with 97,186 (in thousands) as of June 30, 2026.
  • Working capital was 84,370 (in thousands) as of September 30, 2026, compared with 99,093 (in thousands) as of June 30, 2026.
  • Total stockholders’ equity was 85,948 (in thousands) as of September 30, 2026, compared with 100,687 (in thousands) as of June 30, 2026.

Analysis

Rezolute remains a development-stage company and reported no revenue in the filing. First-quarter fiscal 2027 operating expenses were $ 19,385 (in thousands), compared with $ 19,817 (in thousands) in the same period a year ago. R&D expense was $ 12,807 (in thousands), with the decline attributed to lower ersodetug manufacturing and patient-affairs costs, partly offset by higher employee-related stock-based compensation. G&A expense was $ 6,578 (in thousands), reflecting lower professional fees partly offset by higher employee-related stock-based compensation.

The lower operating expense base did not translate into a narrower reported net loss. Net loss was $ (18,487 ) (in thousands), compared with $ (18,150 ) (in thousands) a year earlier, as non-operating income, net declined to $ 898 (in thousands) from $ 1,667 (in thousands). Basic and diluted net loss per common share was unchanged at $ (0.18 ).

Liquidity declined during the quarter. Cash, cash equivalents and investments in marketable securities were $90.0 million at September 30, 2026, versus $107.8 million at June 30, 2026. The balance sheet also reported working capital of 84,370 (in thousands), total assets of 96,010 (in thousands), and total stockholders’ equity of 85,948 (in thousands) as of September 30, 2026.

The principal near-term clinical event is topline data from the tumor HI upLIFT Phase 3 study, expected by mid-December 2026. Enrollment is complete, and the Company said 7 of the 8 participants enrolled in the first half met the responder criterion for the primary endpoint; the remaining participant was classified as a non-responder after discontinuing study drug. For congenital HI, FDA recommended a BLA filing after a pre-BLA meeting, but sunRIZE did not meet its primary endpoint. The Company plans to submit a BLA for ersodetug for one or potentially both indications in 2027.

Not in the filing

stated, not guessed
  • Revenue and revenue comparisons were not reported.
  • Segment revenue and segment comparisons were not reported.
  • Gross margin was not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Debt was not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • Tax rate was not reported.
  • Financial guidance for revenue, gross margin, operating expenses, or tax rate was not reported.
  • Prior earnings outlook was not provided, so comparison with prior guidance is unavailable.
  • Named executive commentary and attributable executive quotes were not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Fourth quarter and full fiscal year 2026

AlphAI · Earnings readRZLT · Fourth quarter and full fiscal year 2026 · ended June 30, 2026

Rezolute reported lower fourth-quarter net loss and R&D expense, while full-year net loss increased and congenital HI Phase 3 regulatory uncertainty remained unresolved.

→Mixed quarter

Fourth-quarter operating expenses and net loss declined from the prior-year period, and the tumor HI upLIFT study produced responder updates. However, full-year net loss increased, cash and marketable securities declined, and the congenital HI sunRIZE study did not meet its primary endpoint.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Fourth quarter fiscal 2026 research and development expensesGAAP$14.9M––
Full fiscal year 2026 research and development expensesGAAP$53.8M––
Fiscal 2026 research and development share-based compensation expenseGAAP$6.5M––
Fourth quarter fiscal 2026 general and administrative expensesGAAP$6.7M––
Full fiscal year 2026 general and administrative expensesGAAP$29.2M––
Fiscal 2026 general and administrative share-based compensation expenseGAAP$8M––
Fourth quarter fiscal 2026 total operating expensesGAAP$21.56M––
Full fiscal year 2026 total operating expensesGAAP$82.97M––
Fourth quarter fiscal 2026 loss from operationsGAAP(21,562 )––
Full fiscal year 2026 loss from operationsGAAP(82,966 )––
Fourth quarter fiscal 2026 non-operating income, netGAAP1,071––
Full fiscal year 2026 non-operating income, netGAAP5,380––
Fourth quarter fiscal 2026 net lossGAAP$20.5M––
Full fiscal year 2026 net lossGAAP$77.6M––
Fourth quarter fiscal 2026 basic and diluted net loss per common shareGAAP$ (0.20 )––
Full fiscal year 2026 basic and diluted net loss per common shareGAAP$ (0.75 )––
Fourth quarter fiscal 2026 shares used to compute basic and diluted net loss per common shareGAAP104,488––
Full fiscal year 2026 shares used to compute basic and diluted net loss per common shareGAAP103,907––
Cash and cash equivalents as of June 30, 2026GAAP$10.62M––
Investments in marketable debt securities as of June 30, 2026GAAP97,186––
Working capital as of June 30, 2026GAAP99,093––
Total assets as of June 30, 2026GAAP112,849––
Accumulated deficit as of June 30, 2026GAAP(481,442 )––
Total stockholders’ equity as of June 30, 2026GAAP100,687––

What drove it

  • Enrollment is in progress in the upLIFT Phase 3 study in tumor HI, with topline results expected before the end of 2026.
  • Of the 8 participants enrolled in upLIFT, 6 had met the responder criterion within the 8-week pivotal treatment phase as of the June 2026 announcement, and the seventh participant subsequently met the responder criterion.
  • Each of the 6 participants that had met the responder criterion at the June 2026 announcement achieved complete discontinuation of intravenous glucose requirements with ersodetug.
  • The decrease in fiscal year 2026 R&D expenses was primarily due to decreased manufacturing costs for ersodetug, partially offset by increased employee-related stock-based compensation expense.
  • The increase in fiscal year 2026 G&A expenses was primarily attributable to increased employee-related stock-based compensation expense and increased professional fees in preparation for future ersodetug commercial activities.

Concerns

  • The Phase 3 sunRIZE study in congenital HI did not meet its primary endpoint.
  • Data from sunRIZE remains under review with the FDA.
  • The Company stated that the FDA could determine that the only path forward for the congenital HI indication is a new randomized control trial similar to sunRIZE.
  • Full fiscal year 2026 net loss was $77.6 million compared to net loss of $74.4 million for the fiscal year 2025.
  • Cash, cash equivalents and investments in marketable securities were $107.8 million as of June 30, 2026, compared with $167.9 million as of June 30, 2025.

What to watch

  • Completion of upLIFT enrollment and topline results expected before the end of 2026.
  • FDA feedback on the congenital HI sunRIZE data package and whether the Agency requests a new randomized control trial.
  • Ongoing participation and glycemic-control indicators in the sunRIZE open-label extension phase.
  • Further changes in R&D manufacturing costs, employee-related stock-based compensation expense, and professional fees associated with potential ersodetug commercial activities.

Balance sheet and cash flow

  • Cash, cash equivalents and investments in marketable securities were $107.8 million as of June 30, 2026, compared with $167.9 million as of June 30, 2025.
  • Working capital was 99,093 as of June 30, 2026, compared with 159,233 as of June 30, 2025.
  • Total stockholders’ equity was 100,687 as of June 30, 2026, compared with 162,127 as of June 30, 2025.

Analysis

Rezolute remains a development-stage company, with no revenue reported in the filing and financial performance defined by clinical-development spending and investment income. Fourth-quarter R&D expenses were $14.9 million compared with $20.9 million for the same period a year ago, while fourth-quarter net loss was $20.5 million compared with a net loss of $24.4 million. The lower quarterly R&D expense was the principal contributor to the reduced quarterly loss.

The full-year picture was less favorable on operating costs and loss. Fiscal 2026 R&D expenses were $53.8 million compared to $61.5 million in fiscal year 2025, with the decrease primarily attributed to lower ersodetug manufacturing costs. However, G&A expenses increased to $29.2 million from $18.4 million, driven by employee-related stock-based compensation expense and professional fees for prospective ersodetug commercial activities. Full-year net loss increased to $77.6 million from $74.4 million.

Liquidity declined over the year. Cash, cash equivalents and investments in marketable securities were $107.8 million as of June 30, 2026, compared with $167.9 million as of June 30, 2025. The balance sheet also showed working capital of 99,093 versus 159,233 and total stockholders’ equity of 100,687 versus 162,127. The filing did not report operating cash flow, free cash flow, debt, capital-return activity, or financial guidance.

The operating update centers on ersodetug clinical and regulatory milestones. In tumor HI, upLIFT enrollment is in progress and topline results are expected before the end of 2026. The Company reported that 6 of 8 enrolled participants had met the primary-endpoint responder criterion within the 8-week pivotal treatment phase as of its June 2026 update, with a seventh participant subsequently meeting the criterion. In congenital HI, sunRIZE did not meet its primary endpoint, and the Company continues to await FDA feedback after providing additional data and analyses.

The critical near-term variables are the upLIFT topline outcome and the FDA’s view of the sunRIZE evidence. Rezolute stated that the Agency could conclude that a new randomized control trial similar to sunRIZE is the only path forward for congenital HI, which the Company said would adversely affect its ability to pursue that indication and the commercial potential for ersodetug. The filing therefore presents positive tumor HI study progress alongside unresolved congenital HI regulatory risk and a lower year-end liquidity position.

Not in the filing

stated, not guessed
  • Revenue
  • Segment revenue and segment profitability
  • Gross profit and gross margin
  • Non-GAAP financial measures
  • Prior-quarter comparisons
  • Operating cash flow
  • Free cash flow
  • Debt and other liabilities
  • Capital returns, including share repurchases and dividends
  • Financial guidance for revenue, gross margin, operating expenses, tax rate, or other financial metrics
  • Named executive quotes

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about RZLT earnings dates

When is Rezolute's next earnings date?
AlphAI has no date for RZLT yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.